

## **Atlantic Pharmaceuticals, Inc. Announces Completion of a Pre-IND Meeting with FDA for a Tamper Resistant Immediate Release Oxycodone**

Atlanta, GA, March 28 2011 – Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that the Company has completed a Pre- Investigational New Drug (PIND) Meeting with the Food and Drug Administration (FDA) for regulatory guidance in submitting a tamper-resistant SMART/Script™ formulated immediate release oral oxycodone (ATLP-02).

SMART/Script™ (SMART / Simple, Controllable, Resistant, Insoluble, Physical Trap) is a physicochemical, abuse deterrent formulation technology utilized for short or long acting commonly abused oral medications such as opioids and amphetamines.

Atlantic's ATLP-02 formulated with SMART/Script™ is an immediate release oral dosage form of oxycodone that is designed to be more resistant to tampering and abuse than the current products available. Once the drug is loaded into the capsule, it is difficult to fully extract in common injectable solutions. Crushing ATLP-02, such as by chewing or hammering, will lead to a potential decrease in the release of the drug in gastro intestinal conditions and advanced solvents.

We are pleased to have had a successful meeting with the FDA and have a full understanding of the requirements necessary to approval ATLP-02," said Anthony Soccia, President, Atlantic Pharmaceuticals.

### **ABOUT SMART/SCRIPT**

SMART/Script™ (SMART / Simple, Controllable, Resistant, Insoluble, Physical Trap) is a physicochemical, abuse deterrent formulation technology utilized for short or long acting commonly abused oral medications such as opioids and amphetamines. Formulating with SMART/Script™ allows for the potential reduction in misuse with certain types of pharmaceuticals products. If the drug is intentionally or accidentally chewed or otherwise physically destroyed, SMART/Script's™ inactive ingredients (referred to as the drug TRAP) will agglomerate with and may sequester the drug matrix thereby decreasing or slowing drug diffusion and release out of the dosage form.

### **ABOUT ATLANTIC**

Atlantic Pharmaceuticals, Inc., is a privately held specialty pharmaceutical company dedicated to the discovery and development of innovative, late stage therapies for substance abuse and pain related conditions. For more information, visit the Company's website at [www.atlanticpharma.com](http://www.atlanticpharma.com)

Contact

Anthony Socia

Phone: 404-994-5135

Atlantic Pharmaceuticals, Inc.

[info@atlanticpharma.com](mailto:info@atlanticpharma.com)